We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction.
UNLABELLED The present study attempts to assess the efficacy combination therapy for heart failure . Genuine dose-response studies on combination therapy are not available and published studies involved adding one drug on top of ' usual treatment ' . Sixteen different dosage combinations of tr and olapril and bumetanide was tested in a double blind , double placebo-controlled , r and omized , multiple cross-over study in a 16 times six balanced incomplete Latin square design . Patients reported optimal quality of life on the sub maximal dose bumetanide . Bumetanide decreased left ventricular function and increased heart rate and plasma noradrenaline in a dose dependent manner . Doses of bumetanide of more than 0.5 mg , given twice daily significantly decreased the quality of life and increased diuresis . Weight loss was maximal on 0.5 mg bumetanide twice daily . Tr and olapril significantly reduced systolic blood pressure with the maximal effect at 0.5 mg daily . Both drugs significantly increased renin concentration with a significant potentiating interaction . It was not possible to detect beneficial effects of combination therapies . The optimal dosage of Bumetanide appeared to be 0.5 mg twice daily based on its effect on quality of life and weight loss . Estimated by the reduction in systolic blood pressure the optimal dosage of Tr and olapril appeared to be 0.5 mg once daily . CONCLUSIONS It appears that patients should be given less than the usually recommended dosages . Patients may be treated with a low dose loop diuretic , if signs of water retention are present or if symptomatic relief is desired
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .